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The use of estrogens in postmenopausal women

has become

controversial. Estrogen replacement therapy has been used for many years to
slow the progression of atherosclerosis. However, recent clinical studies have
shown that menopausal women on hormone replacement therapy have higher
incidences of myocardial infarctions and strokes than their counterparts without
the therapy. Other studies have demonstrated that a decrease in collagen content
in advanced atherosclerotic lesions may weaken the structural integrity of these
lesions, resulting in rupture and clot formation. Within lesions, vascular smooth
muscle cells (VSMCs) actively synthesize collagen and other types of extracellular
matrix proteins during atherogenesis. Estrogen, through activation of the second
messenger cAMP, may attenuate collagen synthesis in VSMCs and may promote
reduction of collagen content in lesions.
Incubation with Rp-cAMPs, a PKA inhibitor, blocked estrogen's ability to
inhibit collagen synthesis in VSMCs. This suggests that estrogen, through
stimulation of cAMP, may activate the cAMP-PKA pathway in VSMCs. Treatment
of VSMCs with estrogen and phophodiesterase inhibitors, cilostamide or Ro-201724, had an additive effect on increasing cAMP levels and on inhibiting collagen
synthesis. VSMCs treated with estrogen and forskolin, an adenylyl cyclase
stimulator, also had an additive effect on increasing cAMP levels
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and on attenuating collagen synthesis. When VSMCs were treated with both estrogen
and a beta-adrenergic agonist, isoproterenol or terbutaline, there was an additive effect
on cellular cAMP levels although the observed decrease in collagen synthetic rates
were the same as observed in estrogen treated cells. VSMCs, which were treated with
terbutaline, had a significantly higher amount of

cAMP located extracellularly

compared to estrogen treated cells. The different distribution patterns of cAMP
observed in terbutaline and estrogen treated cells may explain why beta agonists may
not attenuate collagen synthesis in VSMCs. These results clearly demonstrate that not
all agents, which elevate cAMP, may inhibit collagen synthesis in VSMCs. Our data
also suggest that the combination of agents, which have an additive effect with
estrogen, may have a negative effect on the stability of existing atherosclerotic lesions
through the inhibition of collagen synthesis.
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Introduction
Pathogenesis of Atherosclerosis

Cardiovascular disease, accounting for approximately one million deaths
annually, remains as the primary cause of death in the United States (National
Institutes of health, 2002). Most cardiovascular deaths are attributed to myocardial
and

cerebral infarctions in

blood

vessels that exhibit atherosclerosis.

Atherosclerosis is a disease primarily of the large to medium- sized arteries, which
is characterized by raised focal plaques or lesions within the intima and media of
the blood vessels. As plaques enlarge, they can impede blood flow to tissue
causing tissue necrosis and death. Atherosclerotic plaques can also serve as a
focal point for the formation of blood clots, which if large enough can completely
stop blood flow to tissues. (Parrish et al., 1967) The fatty streak is thought to be
the earliest type of atherosclerotic lesion. It is a lipid-rich lesion, consisting of both
lipid-laden macrophages and vascular smooth muscle (VSMCs) (McGill et al.,
1968).

With increasing age, the fatty streak may progress and become an

advanced, complicated plaque, composed of increased amounts of VSMCs,
leukocytes, and intracellular and extracellular lipids (Ross et al., 1986). This type
of lesion is often surrounded by a dense fibrous cap of VSMCs and collagen (Fig.
1) and is referred to as a fibrous plaque (Ross et al., 1986).
The exact cause of atherosclerosis is unknown, however, factors, such as
hypertension, hypercholesterolemia, diabetes, smoking, and bacterial or viral
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Fig 1. An advanced atherosclerotic lesion.

infections are major risk factors for the development of atherosclerosis (Ross et
al., 1976). Work by Ross and others suggest that these risk factors induce injury
to the endothelial lining that initiates a variety of responses in the vascular wall,
ultimately resulting in the formation of an atherosclerotic plaque (Ross et al.,
1993) (Fig.2).
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Fig. 2 A schematic showing major risk factors causing injury to the arterial wall which results in
the pathological manifestations of atherosclerosis.

The Initiation of Atherosclerosis

Both animal and human studies have suggested that atherosclerotic
lesions are characterized by endothelial dysfunction, which is caused by injury
to the endothelial lining of blood vessel (Petterson et al., 1993). In response to
injury, endothelial cells begin to express adhesion molecules, selectins,
intercellular adhesion

molecule-1 (ICAM-1) and vascular cell adhesion

molecule-1 (VCAM-1]). These molecules are believed to aid in the recruitment
of monocytes, T- lymphocytes, and other immune cells. (Cybulsky et al., 1991).
Additionally, synthetic VSMCs stimulate monocyte and leukocyte recruitment
during the early stages of atherogenesis by expressing VCAM-1 and ICAM-1

(Landry et al., 1997 and Poston et al., 1992).
The expression of granulocyte-macrophage colony stimulating factor
(GM-CSF), macrophage colony stimulating factor (M-CSF), and monocyte
chemotactic protein 1 (MCP-1) by endothelial cells and activated macrophages
have been reported to contribute to the early development of atherosclerotic
lesions (Rajavashisth et al., 1990 and Boisvert et al., 1998). MCP-1 has been
shown to promote chemotaxis and accumulation of additional monocytes to
areas of lesion development (Boisvert et al., 1998). GM-CSF and M-CSF have
been shown to stimulate differentiation, proliferation, and migration of
macrophages and granulocytes, suggesting that these molecules may act as
regulatory signals for modulating cell migration and proliferation during the early
stages of atherogenesis. (Rajavashisth et al., 1990, Metcalf et al., 1989,
Bussolino et al. 1989) .

VSMC in Atherosclerosis
Migration and proliferation of aortic vascular smooth muscle cells (VSMC)
may play an important role in the formation of atherosclerotic lesions. Following
injury to the endothelial lining VSMC become phenotypically altered and
participate in the repair process of endothelial lining. Ross et al. (1993) have
suggested that VSMC involvement during the repair process may become
uncontrolled and may contribute to the formation of atherosclerotic lesions.
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Phenotypic Regulation. VSMCs can present either a contractile or synthetic

phenotype. In normal blood vessels, the majority of VSMCs are in a contractile
phenotype and express a unique array of contractile proteins, receptors, ion
channels, signaling molecules, and other proteins involved with cellular
contraction (Owens et al., 1998). Contractile VSMCs proliferate and synthesize
extracellular matrix proteins at extremely low rates, but once converted to a
synthetic phenotype, as seen in vascular remodeling, these cellular processes
are accelerated (Owens et al., 1995). The conversion of VSMCs to the synthetic
phenotype is characterized by a reorganization of cytoplasmic microfilaments
and organelles. Thyberg et al (1983) has shown that synthetic VSMCs have a
reduced number of microfilaments and a larger number of organelles, such as
rough and smooth endoplasmic reticulae, golgi, lysosomes, and mitochondria,
which are responsible for the biosynthesis and secretion of macromolecules,
such as collagen and glycosaminoglycans.
Several studies have demonstrated that, during the atherogenic process,
contractile VSMCs are transformed into synthetic VSMCs (Campbell et al 1981).
The precise mechanism, by which VSMCs undergo a phenotypic transformation,
remains elusive. Studies have shown that certain cytokines and prostaglandins
promote the transition of VSMCs from a normal contractile phenotype to a
synthetic one (Ross et al., 1981). MCP-1 and eicosanoids, such as, platelet
derived 12-hydroxyeicosatetraenoic acid, neutrophil derived leukotriene B4,
leukotrienes C4, D4, E4, and prostaglandin E1, all have been shown to be
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possible inducers of the secretory phenotype (Sjolund et al., 1984, Palmberg et al.,
1989 and Denger et al., 1999).
In vitro studies have shown that culturing VSMC in fetal calf serum
promotes conversion to the synthetic phenotype (Hedin et al., 1987). It is
believed that growth factors in fetal calf serum induces phenotypic conversion,
resulting in proliferation of cultured VSMCs (Hedin et al., 1987). Other studies,
examining VSMC growth on various types of matrix proteins, have reported that
the extracellular milieu may play a role in phenotypic regulation of VSMCs.
Contractile VSMCs cultured on type I collagen or fibronectin displayed
conversion to the synthetic phenotype without the addition of exogenous
mitogens (Thyberg et al., 1990). On the other hand, VSMCs grown on
glycoprotein, laminin, or elastin, exhibited cell attachment, suppression of
spreading, and retention of the contractile phenotype for several passages
(Thyberg et al., 1990). Yamamoto et al. demonstrated that antibody blockage of
the beta-1 integrin receptor in synthetic VSMCs prevented phenotype transition.
These data suggest that VSMC integrin receptors are important for matrix-cell
interactions, and the attachment to matrix proteins may promote VSMC
phenotype modulation during atherogenesis (Yamamoto et al., 1993).
Inducers of VSMC Proliferation and Migration During Atherogenesis.

A host of diverse molecules, released from dysfunctional endothelial cells,
platelets, synthetic VSMCs and/or various infiltrating immune cells, may alter the
activity of synthetic VSMCs (Ross et al., 1976). MCP-1, basic fibroblast growth
factor (bFGF), and platelet-derived growth factor B-chain (PDGF-BB) have been
shown to stimulate proliferation of synthetic VSMCs (Viedt et al., 2002 and Linder
et al., 1995).
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Studies with adult rat synthetic VSMCs have shown that VSMCs are able to
secrete a PDGF-like mitogen, which promotes cellular proliferation (Sjolund et
al., 1988).
Interleukin-1 and tumor necrosis-alpha (TNF-α), released by macrophages, also
stimulate VSMC proliferation in addition to inducing VSMC expression of MCP1 (Cattaruzza et al., 2002). lnterleukin-3, which is secreted by activated T
lymphocytes and is found in atherosclerotic lesions, may support atherogenesis
by promoting proliferation and migration of VSMC within lesions (Brizzi et.,
2001).
A variety of blood products can also stimulate VSMC migration and
proliferation. At the site of blood vessel injury, platelets release heparinase and
platelet factor 4, promoting the release of bFGF from the extracellular matrix of
blood vessels. The release of bFGF has been shown to induce VSMC
proliferation (Myler et al., 2002). Thrombin, a known mitogen of VSMCs, can also
induce VSMC expression of the urokinase-type plasminogen activator.
Urokinase-type plasminogen activator degrades fibrin through the conversion of
plasminogen to plasmin, and. it is thought that this process promotes VSMC
migration (Reuning et al., 1994). Other studies have shown that blood
coagulation factors X, Xa, and protein S can also stimulate VSMC proliferation
(Gasic et al., 1992).
Other Possible Roles of Synthetic VSMCs. In addition to proliferative and
migratory roles during atherogenesis, synthetic VSMCs have the
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ability to synthesize various types of macromolecules, which are involved in
vascular remodeling in response to endothelial injury. (Ross et al., 1976). In
response to PDGF treatment, cultured rat arterial VSMCs were shown to secrete
MCP-1 (Poon et al., 1996). Poon et al. concluded that MCP-1 expression is a
highly regulated process, which may be important in contributing to the
inflammatory process during atherogenesis. In vitro studies have shown that
MCP-1 induces interleukin-6 release from VSMCs (Viedt et al., 2002).
lnterleukin-6 promotes differentiation of B lymphocytes into plasma cells that
secrete

antibody

immunomodulators

against
may

various

contribute

components
to

continuous

of

lesions.

inflammation

These
within

atherosclerotic lesions (Hansson et al., 1989 and Libby et al., 1995). GM-CSF,
which is released from endothelial, can also be secreted by VSMCs, suggesting
that both endothelial cells and VSMCs can stimulate proliferative activity in
addition to inducing the migration of macrophages and granulocytes at the site
of inflammation during the early stages of atherogenesis (Stanford et al., 2002).
TNF-α, produced by both immune cells and endothelial cells and increases
inflammatory and immune responses, is also released by VSMCs (Newman et
al., 1998). The release of TNF-α by VSMCs may cause the infiltration of
lymphocytes into lesions and may induce their activation (Newman et al., 1998).
VSMC and Connective Tissue

Synthetic VSMCs can synthesize enormous amounts of connective tissue
proteins that promote vascular remodeling during atherogenesis (Burk et al.,
1979). Numerous types of connective tissue proteins (i.e., collagen, fibronectin,
proteoglycans, elastin) are essential in sustaining

9

the synthetic VSMC phenotype (Pietila et al., 1983). During atherogenesis,
collagen production by VSMCs exceeds the synthesis of all other types of
connective tissue proteins, and, thus, comprises the bulk of the lesion (Pietila et
al., 1983).
The Role of Collagen in Atherosclerotic Lesion Development

It is well known that collagen molecules are structural macromolecules
abundantly found in the extracellular matrix (ECM). Collagens are a family of
complex proteins, which are comprised of 19 genetically distinct types (Wight et
al., 1997). The general structure of collagen consists of a triple helix of
polypeptide chains and globular domains. Collagen is unique in that it contains
high amounts of the amino acid, hydroxyproline. Besides playing a structural role
in vascular tissue, collagen has been shown to be involved with atherosclerotic
lesion formation and lesion stability. High levels of collagen within lesions may
lead to occlusions in blood vessels, while a deficit in collagen levels may make
lesions more susceptible to rupture (Rekhter et al., 1998)
Collagen comprises 60% of total protein within lesions (Smith et al., 1965).
Collagen accumulation within lesions contributes to arterial lumen narrowing and
may also further lesion development by serving as a depot for macromolecules,
such as modified lipoproteins and growth factors (Greilberger et al., 1997,

Taipale et al., 1997, and Vlassara et al., 1998). Studies have reported that
collagens can interact with extracellular components in blood vessel walls, which
may contribute in lesion development (Wright et al., 1989) Wight et al., (1989)
observed that advanced atherosclerotic lesions that are abundant in type I
collagen are also abundant in glycosaminoglycans (GAGs). In vitro studies have
shown that GAGs can strongly link LDL to type 1 collagen, promoting retention
of LDL in atherosclerotic plaques (Pentikainen et al., 1997). The mechanism by
which GAGs link LDL to collagen is thought to involve both structural and
electrostatic associations. The sulfated groups located on GAGs are highly
negatively charged, and they can electrostatically bind to positively charged LDL
and collagen (Danielson et al., 1997). A study by Hurt, involving isolation of
chondroitin 6-sulfate rich proteoglycan from human aortas, demonstrated that
GAGs bound to LDL via collagen molecules, caused a 2-4-fold increase in the
uptake of cholesterol into human macrophages. Recent studies, employing
electron microscopy and computer modeling, reported that the core protein of
decorin, a predominant type of GAG macromolecule found in atherosclerotic
plaques, has the shape of an arch which can insert itself in the triple helix of type
I collagen (Scott et al., 1996 and Weber et al., 1996).
In vivo studies, using a cholesterol fed rabbit model, demonstrated that
hypercholesterolemia caused the formation of atherosclerotic lesions with a
simultaneous increase in both LDL and GAG metabolism uptake and the
formation of LDL complexes of GAG in association with collagen (Srinivasan et
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al., 1975). Hoover et al., 1996 provided evidence that once LDL undergoes
oxidative or metabolism, the resultant oxidized LDL binds to collagen. These data
suggest that the internalization of oxidized LDL by macrophages may require the
presence of both GAGs and collagen. Studies have also shown that oxidizedLDL may be a stimulant of collagen synthesis in aortic VSMCs. Jimi and
colleagues (1995) found that oxidized-LDL increases collagen synthetic rates
six- fold, while the native form of LDL had no effect in VSMCs. These studies
suggest that oxidized LDL may help to initiate and sustain collagen synthesis in
VSMCs (Jimi et al., 1995).
The Role of Collagen in Lesion Stability
Vulnerable atherosclerotic lesions can rupture and provide a site for the
formation of a vessel-occluding blood clot, culminating in the clinical syndromes
associated with many vascular diseases such as myocardial infarction or stroke.
(Rabbani et al., 1999). The hallmarks of a vulnerable plaque include a large lipid
pool, an abundance of inflammatory cells and mediators, a decreased smooth
muscle cell population, reduction in collagen content, and a thin overlying fibrous
cap (Rabbani et al., 1999). Rupture can commonly occur at the shoulder regions
of lesions where the overlying fibrous cap is thin, necrotic and continuously
infiltrated by macrophages (Constantinides et al., 1966). The shoulder regions of
plaques are regions, which are exposed to the greatest hemodynamic forces
(Cheng et al., 1993). The lipid core within lesions reduces the load-bearing
capabilities because of decreased tensile strength (Macisaac et al., 1993). This

12

promotes higher stress levels in the overlying fibrous cap, which may eventually
rupture (Macisaac et al., 1993).
Rises in blood pressure and coronary spasms can cause vulnerable
lesions to rupture (Constantinides et al., 1990 and Nobuyoshi et al., 1991).
Emotional stress and strenuous physical activity have been strongly associated
with acute myocardial infarction (Totter et al., 1990). Both emotional stress and
physical activity may cause myocardial infarct by elevating blood pressure and
triggering coronary spasm. A study by Constantinides et al., 1966, demonstrated
that in animal models, a sudden increase in arterial pressure can promote lesion
rupture. After lesion disruption, the highly thrombogenic lipid components and
the exposed collagen fragments may promote in the formation of an occlusive
thrombus (Falk et al., 1995)
Studies have shown that therapeutic strategies to lower lipid blood levels
contributes to lesion stability (Rabbani et al., 1999). Elevated LDL levels have
been intricately linked with endothelial dysfunction, and a reduction in LDL levels,
using lipid-lowering drugs, has resulted in improved endothelial function
(Anderson et al., 1995). Improving endothelial function by lowering LDL levels
reduces the level of LDL infiltration within blood vessels, which reduces the
amount of LDL that can collect within lesions (Anderson et al., 1995)). Decreased
LDL pools within lesions resulted in a reduction of expressed matrix degrading
enzymes and in an accumulation of interstitial collagen within the intima of
atherosclerotic lesions of rabbits (Aikawa et al., 1998). Aikawa el al. suggested
that lipid lowering may stabilize vulnerable plaques by decreasing the
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degradation of collagen. Additional studies have shown that increases in HDL, which
is responsible for lipid removal from tissues, can increase the plaque's relative
strength by stimulating collagen synthesis, thus favoring lesion stabilization
(Blankenhorn et al., 1989). The conclusion of these findings emphasizes that
circulating levels high LDL and low HDL may affect plaque stabilization by promoting
a better balance between the amount of lipid in a lesion relative to the amount of
collagen in the lesion (Rabbini et al., 1999).
Factors Regulating Collagen Synthesis
There are three primary factors, which may control collagen production
within lesions. They are: 1) cell type, 2) cell activity, such as migration and
proliferation, and 3) chemical and physical factors within atherosclerotic lesions
(Rekhter et al., 1999).
Cell Type
Synthetic VSMCs, which migrate, proliferate, and produce increased
amounts of collagen, are the most important contributors to the development of
fibrous atherosclerotic plaques in blood vessels. Some studies have established that
endothelial cells can also synthesize collagen during capillary vascularization in
thicker plaques (Canfield et al., 1992). Cell types, such as stellate intimal cells and
osteoblast-like cells, have also been shown to produce small amounts of type I
collagen in human atherosclerotic lesions (Tintut et al., 1998 and Rekhter et al.,
1999. (Fig. 3)
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smooth
musclelike cell

Fig. 3. A schematic showing VSMCs and stellate smooth muscle-like cell within a lesion.
Rehkter et al., 1999 Cardiovascular Res 41:376-384.

Chemical and Physical Factors
In adult rat and rabbit aortic VSMC cultures, there is a strong relationship
between the conversion to the synthetic VSMC phenotype and collagen synthesis
(Sjolund et al., 1986). Many studies have shown that upon phenotypic conversion to
the synthetic from the contractile, VSMCs begin to synthesis and release collagen
within the lesion (Thyberg et al., 1996). There are several local chemical factors
which can alter collagen production in VSMCs. (Fig. 4).
PDGFBB
Endothelln-1
IL-1

Fig. 4 A schematic showing a list of factors that may regulate collagen production in VSMCs.
Rekhter et al., 1999 Cardiovascular Res 41:376-384
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Studies of VSMC in culture have shown that PDGF induces synthesis of
type I and Ill collagen. (Amento et al., 1991). The mechanism of PDGF
stimulation of collagen synthesis in VSMCs is unknown. However, it is believed
that PDFG is not a direct stimulator of collagen synthesis but rather a mitogen,
which indirectly stimulates collagen synthesis through increase of cell
proliferation (Rehkter et al., 1999). Interleukin-I, endothelin-I and angiotensin_ll
have also been shown to stimulate collagen synthesis in SMC cultures (Rehkter
et al., 1996). Angiotensin II stimulates collagen production in human arterial
SMCs via the AT(1) receptor which results in an increases production of
transforming growth factor beta {TGF-β) (Ford et al., 1996).
TGF-β is a potent stimulator of collagen in VSMC cultures (Liau et al.,
1989). Nabel et al., has shown that in vivo transfer of the TGF-β gene into VSMCs
of a porcine artery induced type I collagen production (Nabel et al., 1993).
Studies by Brenner et al. (1994), have shown that there is a TGF-β activation
element in the promoter region of the alpha 1 (I) gene, which is responsible for
activating transcription of collagen. Connective tissue growth factor (CTGF), a
protein, which is thought to be a downstream mediator for TGF- β signaling, has
been shown to promote extracellular matrix formation by stimulating collagen
synthesis in several cell types, including vascular endothelial cells, epithelial cells,
neuronal cells, VSMCs, and fibroblasts. Additionally, CTGF has been shown to
promote VSMC proliferation, migration, and adhesion.
CTGF overproduction is proposed to play a major role in pathways that lead to
tissue fibrosis, especially in those tissues that are TGF-β dependent
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(Moussad et al., 2000). CTGF, a 38-kDa cysteine-rich protein, is abundantly
expressed in atherosclerotic lesions, but only marginally expressed in normal
vascular tissues, suggesting that CTGF is one of the factors involved in the
development of atherosclerotic lesions (Fan et al., 2002). Recent studies by
(Duncan et al.,1999) demonstrated that elevation of intracellular levels of
cAMP with either membrane-permeable 8-Br-cAMP or an adenylyl cyclase
activator, cholera toxin, inhibited the ability of both TGF-β and CTGF to
increase collagen synthetic rates in fibroblasts. Chen et al., 1999, investigated
the ability of pentoxifylline to inhibit proliferation and collagen synthesis in rat
VSMCs under both basal and PDGF or TGF-β stimulated conditions.
Pentoxifylline is a phophodiesterase inhibitor that increases cellular levels of
cAMP by preventing its metabolism. Chen and colleagues showed that
pentoxifylline inhibited both VSMC proliferation and collagen synthesis in a
dose dependent manner.
Cyclic AMP has been recognized as an inhibitor of collagen synthesis
for many years. Studies by Baum et al. (1978) were the first to demonstrate in
fibroblasts that elevation of cAMP levels reduced collagen production by as much
as 40%. Increasing the levels of cAMP in cultured lung or skin fibroblasts by
treatment with either prostaglandins, dibutyryl AMP, or the beta- adrenergic
agonist, isoproterenol, resulted in decreased rates of collagen synthesis
(Kollros et al., 1987) Clark et al., 1996 reported that PGE2 stimulated
intracellular cAMP levels and decreased both lung fibroblast proliferation and
collagen production in a dose-dependent manner. Moreland et al., 1998
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investigated the mechanism by which the prostaglandin PGE 1 suppresses TGFβ- induced collagen synthesis in human corpus cavernosum smooth muscle cells.
These studies demonstrated that PGE 1 inhibited TGF-β- induced collagen
synthesis by invoking cAMP synthesis through the activation of adenylyl cyclase
activity.
Other studies using intestinal SMC reported that cholera toxin and isobutyl
methylxanthine, agents which elevate cAMP levels, also significantly inhibited
collagen synthesis. (Perr et al., 1989). The exact mechanism by which increased
cAMP suppresses collagen synthesis is not known. However, because a variety of
agents, which operate through different mechanisms, elevate cAMP levels and
suppress collagen production, it would suggest cAMP plays a central role.
Estrogen and Atherosclerosis
Post-menopausal women in their 50's and 60's experience an acceleration
in coronary heart disease and usually match their male counterparts in the
number of incidences of cardiovascular complications (Witteman et al., 1989).
Estrogen replacement therapy has been used for many years to slow the
progression of atherosclerosis. Recent epidemiological studies have strongly
questioned this use of estrogen since it has shown that post-menopausal women
on estrogen replacement therapy may experience an increased incidence of
cardiovascular disease (Farquhar et al., 2002 and Lemaittre et al., 2002). Prior
to these publications it was generally believed that the administration of estrogen
to post-menopausal women decreased the risk of cardiovascular disease ( for
review see Bittner et al., 2000). The exact
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mechanism of estrogen's perceived antiatherogenic effects has not been
established. Studies suggested that estrogen had both lipid and non-lipid effects.
The lipid effects include estrogen's ability to decrease both total cholesterol and
LDL levels and to increase HDL levels (Bittner et al., 2000 and Lemay et al.,
2002). Some of the non-lipid mechanisms of estrogen action include decreasing
insulin resistance, serum fibrinogen , factor VII, and plasminogen activator
inhibitor-1 (Weidmann et al., 1985 and Kauser et al., 1994). Estrogens were also
reported to maintain endothelial cell integrity, decrease expression of adhesion
molecules, decrease platelet aggregation, inhibit VSMC proliferation, and exert
antioxidant activity (for review, see Mendelsohn et al., 2002). Several studies
have demonstrated that estrogen has a direct effect on inhibiting collagen
synthesis in VSMC (Beldekas et al., 1981). During the early stages of
atherosclerosis, the over production of collagen is an important component in the
formation of complex fibrous atherosclerotic lesions (Okada et al., 1993). The
natural presence or the administration of estrogens may aid in retarding the
progression of plaques via inhibiting collagen synthetic rates in VSMCs.
In vivo experiments, involving estrogen treatment of cholesterol-fed
rabbits and estrogen treatment of renal hypertensive rats have shown that the
administration of estrogen resulted in a reduction of aortic collagen synthesis in
both the rat and the rabbit (Fischer et al., 1981). Ovariectomy of rabbits fed a
high cholesterol diet resulted in an increased formation of atherosclerotic lesions
(Fischer et al., 1981). Too, in cholesterol-fed rabbits an increase in the rate of
aortic collagen synthesis was also evident (Fischer et al., 1981). Estrogen
treatment of ovariectomized cholesterol-fed
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rabbits resulted in fewer atherosclerotic lesions with reduced levels of aortic collagen
(Fischer et al., 1985). These studies suggested to Fischer et al. (1985) that
estrogen's ability to inhibit atherosclerotic lesion formation was a result of estrogen's
ability to reduce the rate of aortic collagen synthesis. These in-vivo observations
were consistent with the initial observations of Beldekas et al., (1981) who found
that treatment of VSMC in vitro resulted in a decreased production of collagen. The
mechanism by which estrogen treatment reduces collagen synthesis is not
completely understood but is probably related to estrogens ability to increase cell
levels of cAMP. Studies by Dubey et al.,(2000) have shown that estrogen treatment
of VSMCs results in a dose dependent increase in cellular levels of cAMP with
corresponding decreases in collagen synthetic rates . Although the exact mechanism
by which estrogen increases cAMP levels is unknown, studies have shown that
stimulation of cAMP by estrogen in aortic VSMCs occurs via a calcium dependent
process that does not involve nuclear transcription, suggesting that estrogen's
effects on cAMP levels are mediated by direct interaction of the hormone with
specific membrane binding sites (Farhat et al., 1996 and Dubey et al., 2000).
Significance of Study
The relationship of estrogen-induced changes in cAMP levels and
collagen synthesis in the presence of other agents is not known. Tissue levels of
cAMP are a product of its rate of synthesis minus its rate of metabolism. Cyclic
AMP is synthesized from ATP by adenylyl cyclase and is regulated by many Gprotein coupled receptor types. Cyclic AMP is eliminated from the cell by a
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combination

of

hydrolysis,

which

is

catalyzed

by

cyclic

nucleotide

phosphodiesterases, and efflux by several plasma membrane transport proteins. In
most instances cAMP produces its effects by activating cAMP- dependent protein
kinases, which in turn phosphorylate a variety of molecules, such as metabolic
enzymes, transport proteins, and numerous regulatory proteins (Chin et al., 2002)
There are several clinically used agents, which have the potential to significantly
alter cell cAMP levels by either altering its rate of synthesis or elimination. Since
changes in cAMP levels could have a significant effect on collagen synthesis in
VSMC, it is important that the relationship of estrogen, cAMP and collagen synthesis
should be investigated. The hypothesis, which was investigated in this study, is that
agents which elevate cAMP, when used in combination with estrogen, will have an
additive effect in inhibiting collagen synthesis in VSMCs.
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Methods
Animals
Male Sprague -Dawley rats (Charles River Laboratories), weighing between
190-220 grams, were used for the purpose of isolating vascular smooth muscle cells
(VSMC). Rats were housed three per cage at 27 °C with a 12-hour light and dark
cycle. Commercial Purina Rat chow and water were provided ad
libitum. All rats were fasted overnight prior to VSMC isolation. All procedures
were approved by the University of Connecticut Animal Care Committee.
Drugs, Cell Culture Reagents, Isotopes, and other Chemicals
1713

Estradiol,

isoproterenol,

propranolol,

terbutaline,

forskolin,

pentobarbital, elastase, collagenase, and trichloroacetic acid were purchased
from Sigma Chemical (St. Louis, MO). Cilostamide and Ro-24-1720 were
purchased from Calbiochem-Novabiochem (San Diego, CA). Hanks Balanced
Salt Solution, Medium 199, fetal bovine serum, penicillin-streptomycin,
kanamycin, and
amphotercin B were purchased from BRL Gibco Life Technologies (Rockville, MD).

[14C] L-proline was purchased from Amersham Pharmacia Biotech (Piscatawey,
NJ). Optiflour scintillation fluid was purchased from Perkin Elmer Life Sciences
(Beltsville, MD).
Isolation of Cells
Rats were killed with a lethal injection of pentobarbital at dose of 120 mg/kg
and the thoracic cavity was opened immediately. The aorta, from the aortic arch to
the femoral bifurcation, was quickly removed and cleaned under cold running tap
water. During this cleaning process the adventitia from each

22

isolated aorta was removed by blunt dissection and the remaining aorta was placed
in sterile Hanks Balanced Salt Solution (HBSS) pH 7.5. HBSS contained 2.7uM
amphotercin B, 250units/ml penicillin-streptomycin and 170uM kanamycin. The
intima from each aorta was removed by scraping with a rubber policeman, and the
remaining medias were minced into small cuboidal pieces in HBSS. The minced
medias were digested in plain sterile Medium-199, pH 7.5,
containing 2mg/ml collagenase and 0.4 mg/ml elastase for 3 hours at 37

°c in a

shaking water bath. After digestion, cells were initially plated in 25 cm flasks and
were left in the flask for eight days. Studies have reported that all freshly isolated
VSMCs should be in the synthetic phenotype by the eighth day in culture (Thyberg
et al., 1983). Following the eighth day, VSMCs were divided and replated into two
separate flasks, and the cells were allowed to grow to confluency. This step was
repeated eight times to propagate adequate numbers of cells for experiments.
Characterization of VSMCs
Two methods were used to characterize VSMCs following isolation from
aorta. The first method consisted of immunohistochemistry of a specific isoform
of the alpha-actin cytoskeletal protein exclusively found in VSMCs. The second
method included morphological studies of VSMCs in confluent cultures.
Confluent VSMCs have a characteristic "hill and valley" pattern that can be
identified in cultures.
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immunohistochemistry

To assess the identity of VSMCs after isolation, detection of VSMC actin
levels was conducted with the Ultra Streptavidin Detection System (Signet
Laboratories, Dedham, MA). The primary antibody used in this study is specific
for the actin that is only found in VSMCs (Owens et al., 1986). Isolated cells were
grown on cover slips for 24 hours and then were fixed with 100% acetone for
four minutes. Samples were rinsed with phosphate buffered saline (PBS) for
three minutes and then were treated for five minutes with normal serum to block
nonspecific binding. Primary antibody, specific for VSMC actin, was incubated
with samples overnight at 4°C. Primary antibody serial dilutions of 1:40, 1:30,
and 1:20 were used on test samples to ascertain correct dilution for adequate
staining of VSMCs. This step demonstrated that 1:30 dilution was optimal for
staining VSMCs. After the primary antibody wash step, cytology samples were
incubated

with

biotinylated

anti-immunoglobulin

serum

linking

reagent

(secondary antibody) for 20 minutes at room temperature, and the peroxidase
labeled ultra-streptavidin was incubated with samples for an additional 20
minutes at room temperature. The first 20-minute incubation allowed the binding
of secondary antibody to the primary antibody, while the second 20-minute
incubation allowed the peroxidase to bind the secondary antibody. Lastly, the
substrate chromogen, 3-amino-9-ethylcarbazole (AEC), was incubated with
samples for five minutes at room temperature to allow the chromogen to react
with the peroxidase. The counterstain used in these samples was Mayer's
hematoxylin.
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Experimental Conditions
. Each experiment consisted of incubating VSMCs with various
experimental agents for one hour. VSMCs were plated with M-199 medium and
15% bovine serum in six well plates with a diameter of 35mm, and these cells
were then grown to 70-80% confluency. Before experimentation, each well was
washed twice with plain M-199 medium, and the appropriate agent(s) was/were
prepared in M-199 medium and dispensed in duplicate or triplicate into
designated wells. Separate studies were conducted for ascertaining cAMP levels
and protein synthetic rates. To reduce variability, the values obtained from twothree separate wells were averaged and were reported as a single experimental
value (N=1) for all studies.

Determination of Protein Synthetic Rates

[14C]-L-Proline Incorporation [14C]-L-proline incorporation was utilized to assess the
rate of collagen, and non-collagen, protein synthesis in VSMCs. Treated cells
were incubated with isotope for one hour at 37°C. Preliminary studies were
conducted to determine the proper conditions for incorporation of

14

C-proline. The

results of these studies suggested that a 1-hour incorporation would allow for
accurate determination of either inhibition or stimulation of protein synthetic rates. In
all experiments VSMCs were incubated with experimental agents and isotope for 1
hour. Upon completion of the 1- hour incubation period, controls and treated
samples were placed on ice. Cell medium was aspirated from each well and placed
in an equal volume of ice cold 10% TCA.

The cells in
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each well were loosened by scrapping and were then suspended in 100mM EDTA.
VSMCs were then sonicated 3 times for 30 seconds, and 100ul of the resulting
homogenate was set aside for assessing the total protein concentration for
normalizing the collagen and non-collagen synthetic rates (e.g., cpms/mg/ml
protein). The remaining protein in the cell homogenate was precipitated in 5% TCA
by adding an appropriate volume of 10% trichloroacetic acid (TCA) to each sample.
Both cell medium and homogenates were then combined and centrifuged at low
speeds (800xg) for 5 minutes.
Supernatant, containing unincorporated [14 C]-L-proline, was discarded,
and the pellets were resuspended with 4ml of 5% TCA and centrifuged at 800xg
for five minutes. This wash step was repeated 6 times to ensure that all
unincorporated [14 C]-L-proline is removed.

Trichloroacetic Acid Extraction Assay
The hot TCA extraction procedure was utilized to separate collagen from
other cell proteins. The amount of collagen in tissues can be estimated by
measuring tissue levels of hydroxyproline, an amino acid which is primarily found
only in collagen. Hydroxyproline in collagen is formed by the post-translational
hydroxylation of one of the prolines in the repeating amino sequence of G-P-P,
which is common to collagen. Studies have reported that treatment of collagen
with TCA at 90°C solubilizes collagen by hydrolysis of the peptide bond between
proline and hydroxyproline (Last et al., 1975). In our studies, after samples were
treated with 90° C TCA the supernatant was collected and was used to assess
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collagen synthesis, and the remaining pellet was used to determine non-collagen
protein synthesis.
Homogenate samples were hydrolyzed in 5% TCA by incubating the
samples in a 90

°c water bath for 60 minutes. The hydrolyzed samples were then

centrifuged at 800xg for 10 minutes. Supernatant samples, containing collagen,
were collected in separate tubes and the pellets, consisting of non-collagen protein,
were resuspended with 0.5N NaOH. A 0.5 ml aliquot of each sample (collagen and
non-collagen) was placed in 5ml of scintillation cocktail, and the radioactivity of
incorporated [14C] L -proline was determined by liquid scintillation counting. The
average of two 10-minute counts were used in all experiments to obtain a statistically
significant number of counts. All data were expressed as counts per minute (CPMs).
Cyclic AMP Levels

Cyclic AMP levels were assessed by either the [ 3H] cAMP detection
system (Amersham Pharmacia Biotech, Piscatataway, NJ) or the cAMP enzyme
immunoassay system (EIA) (Amersham Pharmacia Biotech, Piscataway, NJ).
The preparation steps for both cAMP detection systems were identical. After
experimentation, VSMCs were immediately placed on ice. The incubation
medium from VSMCs was removed and placed into separate tubes. VSMCs
were then resuspended in 100mM EDTA and were then sonicated twice for 30
seconds. A 100 µl aliquot from each sample was placed into separate tubes for
determining total protein concentrations. Total protein concentrations were used
for normalizing cellular cAMP levels. The medium and cell homogenate from

27

each sample were combined and boiled for seven minutes to coagulate protein.
Samples were then centrifuged at 800xg for 10

minutes, and the resulting

supernatant was assayed for cAMP content.
Principles and Protocols of cAMP Assays
The [ 3H] cAMP detection system is based on competition between unlabeled
cAMP (sample) and a fixed quantity of tritium labelled cAMP for binding to a protein
which has a high affinity for cAMP (Gilman et al., 1970). The amount of labelled
cAMP -protein complex formed is inversely related to the amount of unlabeled cyclic
AMP present in the assay. The concentration of cAMP in the unknown is assessed
by comparison with a standard curve. (2pmol- 32pmol).
100ul of sample or standard were added to 1.5ml microcentrifuge tubes.
A 50ul aliquot of labeled cAMP was added to each of the samples, which was
followed by the addition of 100ul of binding protein. After a 2-hour incubation
period at 4°C, separation of the protein bound cAMP from the unbound cAMP
(labeled/unlabeled) was accomplished by adsorption of free cAMP on charcoal,
followed by microcentrifugation (800xg) (Brown et al., 1971). A 200ul aliquot of
the supernatant was removed for liquid scintillation counting as described above.
The cAMP enzyme immunoassay system (EIA) is based on competition
between unlabeled cAMP (sample) and a fixed quantity of peroxidase-labelled
cAMP, for a limited number of binding sites on a cAMP specific antibody. The
peroxidase-labeled cAMP conjugate is immobilized onto pre-coated microtiter
plates which is then analyzed on a microplate reader. The amount of cAMP in
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the unknown sample is inversely related to the amount of peroxidase-labelled cAMP,
which is bound to the cAMP specific antibody. The amount of unknown cAMP in
each sample was determined by comparison with a linear standard curve which was
determined for each experiment using a 3200 fmol/ml cAMP standard stock solution.
Beginning with the standards and ending with the unknowns, a volume of
100µl of each sample was added to the specified well plate. Next, a volume of 100µl
of cAMP antibody was added to the sample wells, and these samples were
incubated for two hours at 4°C. Immediately following the 2-hour incubation, 50µl of
cAMP-peroxidase conjugate was added into the wells, and the samples were
incubated for 1 hour at room temperature. Following a wash step to remove excess
antibody, samples were treated with 150µl of tetramethylbenzidine (TMB), which
reacts with the bound cAMP-peroxidase conjugate, for one hour at room
temperature. Upon completion of the enzyme substrate incubation, 100µl of 1.0M
sulfuric acid was added into the well to stop the reaction, and each well was read by
a fluorimeter (Dynex Corporation) at an optical density of 450nm within 30 minutes.
Blank and nonspecific binding wells were included along with the sample wells.
Protein Assays

The Bicinchoninic Acid Protein Assay Kit (BSA) (Pierce, Rockville, IL) or
the Coomassie Plus Protein Assay Kit (Pierce, Rockford, IL) was used to
determine

the

protein

concentrations

of

each

sample.

Total

protein

concentrations were used to normalize cAMP content and collagen, non-
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collagen, and total protein synthetic rates. A Linear standard curve 25-240 g/ml
(BSA) or 1-25 µg/ml (Coomassie,) was used for extrapolating protein concentration
values.
Statistical Analysis

The statistical significance of the data from each study was analyzed by use of a
one-way ANOVA to test for the overall treatment effect. If a significant difference
was indicated, the data was further analyzed using Tukey's procedure. Data which
had a P value of <0.05 ware statistically significant in all experiments.

30
RESULTS

Immunochemical and histological procedures were used to characterize
isolated vascular smooth muscle cells (VSMC). lmmunohistochemistry was
utilized to identify a specific isoform of the α-actin cytoskeletal protein, which is
unique to SMCs. As shown in Fig. 5A, the reddish- brownish staining of α-actin
cytoskeletal filaments, suggests that the isolated cells were VSMCs.
Histologically, the distinct spindle-shape morphology and the hill-valley pattern
of these cells in culture is also a recognized a unique characteristic of VSMCs.
To ensure that the isolated cells were not fibroblasts, mouse fibroblasts were
immunochemically stained for α-actin. As seen in Fig. 5D, the mouse fibroblasts
exhibited an absence of staining for α-actin, which was expected since fibroblasts
lack α- actin.
The ability of estrogen to stimulate the production of cAMP in VSMCs is
shown in Fig. 6 . VSMCs, incubated with increasing concentrations (10-6 104
M) of estradiol for 1 hour, resulted in a corresponding increase in cAMP from
control levels of approximately 10 pmoles/mg protein to 40 pmoles/mg protein.
The effect of increasing concentrations of estradiol on collagen and non-collagen
protein synthesis is shown in Fig. 7. When cells were incubated for 1 hour with
concentrations of estradiol ranging from 10-6 to 104 M there was a corresponding
decrease in the rate of collagen and non-collagen protein synthesis in VSMCs.
The potential correlation between increasing amounts of cAMP and decreasing
rates of collagen synthesis was investigated
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and is shown in Fig. 8. In Fig 4, the percent increase in cell cAMP levels, invoked by
increasing concentrations of estradiol, was plotted against the percent inhibition of
collagen synthesis. Analysis of the data showed a correlation coefficient of 0.88,
which was statistically significant at P <0.1.
The purpose of this study was to examine the relationship of cAMP-protein
kinase and estrogen's ability to inhibit collagen synthesis. Several studies have
shown that cAMP activates the cAMP-protein kinase A pathway to elicit various
cellular processes (Chin et al., 2002). As shown in Fig. 9, treatment of VSMCs
with the protein kinase inhibitor, Rp-cAMP (10-5 M) for 1 hour completely
inhibited estradiol’s (10-5 M) inhibition of collagen synthesis in VSMCs.
The ability of inhibitors of cAMP metabolism to alter cAMP levels and
collagen synthesis, when used alone or in combination with estradiol, was
investigated with phosphodiesterase inhibitors. Treatment of VSMCs with Ro-201724 (10-6 M), an inhibitor of phosphodiesterase type 4, resulted in a significant
increase in cAMP levels. Cyclic AMP levels were approximately 5- fold greater
than the amounts observed with just estradiol alone. When estradiol and Ro-201724 were combined there was a significant increase in cAMP levels compared
to just estradiol treated cells (Fig 10). Treatment of VSMCs with either estradiol
(1. 0 5M) or Ro-20-1724 (10-6 M) resulted in a 50% inhibition of both collagen
and total protein synthesis (Fig 11). The combination of estradiol and Ro-201724 resulted in a reduction in collagen and total protein synthesis,
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which was significantly greater than the reduction observed when either agent
used alone (Fig 11). Treatment of VSMCs with cilostamide (10-6 M), an inhibitor
of phosphodiesterase type 3, also resulted in a significant increase in cAMP
levels (Fig. 12). Cyclic AMP levels were the same as observed with just estradiol
alone. Co-treatment of estradiol and cilostamide resulted in cAMP levels that
were significantly greater than those observed in VSMCs treated with estrogen
alone (Fig 12). Treatment of VSMCs with either estradiol (10-5M) or cilostamide
(10-6 M) resulted in an 50% inhibition of both collagen and total protein synthesis
(Fig 13). The combination of estradiol and cilostamide reduced both collagen and
total protein synthesis, which was significantly greater than the reduction
observed when either agent was used alone (Fig 13) but was similar to the effects
observed when cells were treated with Ro-20-1724 (Fig. 11).
Levels of cAMP and protein synthesis were estimated in VSMCs following
forskolin (10-6M ) induction of adenyl cyclase. Treatment of VSMCs for 1 hour with
forskolin resulted in a significant increase in cAMP levels when compared to either
control or estradiol treated cells (Fig. 14). The combination of VSMCs with estradiol
and forskolin appeared resulted in an increase in cAMP levels (Fig 15). Although
treatment of cells with forskolin resulted in a reduction in collagen and total protein
synthesis, this reduction was similar to the inhibitory effect seen with estradiol
treatment even though forskolin treatment resulted in a much greater increase in
cAMP levels than the increase in cAMP levels produced
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by estradiol. The combination of estradiol with forskolin resulted in a further
reduction in collagen and total protein synthesis (Fig. 15).
Changes in levels of cAMP and collagen and total protein synthesis were
investigated in VSMCs following stimulation or inhibition of autonomic betaadrenergic receptors. Treatment of VSMCs with isoproterenol, a beta agonist,
for 1 hour significantly increased cAMP levels compared to control or estradiol
treated cells (Fig. 16). The combination of estradiol plus isoproterenol resulted in
an additional increase in cAMP levels compared to treatment of VSMCS with
isoproterenol alone. Treatment of cells with propranolol, a beta antagonist, for 1
hour resulted in no significant changes in cAMP levels. The combined treatment
of cells with propranolol plus isoproterenol significantly reduced cAMP levels
compared to cells treated with just isoproterenol. The administration of
propranolol to estrogen treated cells had no significant effect on cAMP levels.
Treatment of VSMCs with isoproterenol, for 1 hour had no significant
effect on collagen or total protein synthesis (Figs 17, 18). This was true whether
the cells were incubated with isoproterenol for 1 hour (Figs.17, 18) or 6 hours
(Fig. 19). Treatment of cells with propranolol had no effect on collagen or total
protein synthesis. The combination of either isoproterenol or propranolol with
estradiol resulted in a decrease in collagen and total protein synthesis, which was
similar to treatment with only estradiol (Fig. 17, 18).
To further evaluate the effects of beta stimulation on VSMC cAMP levels and
collagen and total protein synthesis, cells were treated with terbutaline (10-6 M), a
selective β2 adrenergic agonist. Treatment of cells with terbutaline for 1
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hour resulted in a significant increase in cAMP levels, which was similar to levels
observed in VSMCS with just estradiol alone. When cells were treated with
estradiol plus terbutaline, cAMP levels were significantly greater than the levels
seen in cells treated with just estradiol (Fig. 20). Incubation of VSMCs with
terbutaline had no effect on collagen or total protein synthesis (Fig. 21). When
terbutaline was co-administered with estradiol, the rate of collagen and total protein
synthesis was the same as observed when cells were treated with estradiol alone
(Fig. 21). The ratio of cellular to extracellular location of cAMP following either
estradiol or terbutaline are shown in Fig 22. Following treatment with estradiol
approximately, 40% of cAMP was located intracellularly, while 60% was located
extracellularly. This distribution of cAMP was also observed in non-estradiol treated
control VSMCs. In VSMCs treated with terbutaline, only 10% of cAMP was located
intracellularly and 90% was located extracellularly. This relative distribution of
cAMP was significantly different from the distribution of cAMP seen in control or
estradiol treated VSMCs.
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Fig. 5 lmmunohistochemical identification of alpha-actin in isolated cells. (SA)
isolated cells without alpha-actin antibody. (5B) Isolated eels with alpha-actin staining.;
note the reddish-brownish staining of cells, confirming the presence of alpha-actin. (SC
& D) shows alpha-actin antibody staining of fibroblasts. (SC) fibroblasts, without alphaactin antibody. (5D) Fibroblasts with alpha-actin staining. Note no staining in both the
control and in fibroblasts incubated with alpha-actin antibody.
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Fig. 6. The effect of varying concentrations of estrogen on cAMP levels in VSMCs.
VSMCs were treated with estradiol for one hour and were then assayed for cAMP as
described in methods. In this figure a dose response relationship demonstrates that
increasing estradiol concentrations (10-6 M - 104 M) results in increasing cAMP levels
(pmoles/mg protein) in VSMCs. Each point represents the mean of three observations
which is plotted as mean +/- S.E.
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Fig. 9. The effects of Rp-cAMPs on estradiol's inhibition of protein synthesis in
VSMCs. VSMCs were incubated with agents and 14C-L-proline for one hour and were
assayed for protein synthetic levels as described in methods. Estradiol 10·5 M reduced
collagen synthesis. Rp-cAMPs 1o.s M had no effect on collagen synthesis. Estradiol
1o.s M + Rp-cAMPs 10·5 M treatment had no effect on collagen synthesis. Each value
represents the mean±: SE of five observations. * p< 0.05 compared to control cells. I.
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Fig. 10. The effects of estradiol and Ro-20-1724 on cAMP levels in VSMCs. VSMCs
were incubated with agents for one hour and were assayed for cAMP as described in
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Fig. 11. The effects of estradiol and Ro-20-1724 on collagen and total protein
synthetic rates in VSMCs. . VSMCs were incubated with agents and 14C-L-proline for
one hour and were assayed for collagen and total protein synthetic rates as described
in methods. Estradiol 10-S M and Ro-20-1724 (Ro) 10-6 M reduced both collagen and
total protein synthesis by 50%. Treatment of VSMCs with estradiol 10-5 M
+ Ro-20-1724 10-6 M significantly reduced collagen and total protein synthesis when
compared to treatment of cells with estrogen or Ro-20-1724 alone. Each value represents
the mean ±_SE of six observations. * p< 0.05 compared to control cells. ** p< 0.05
compared to estradiol or Ro-20-1724 treated cells.
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were incubated with agents for one hour and were assayed for cAMP as described in
methods. Estradiol (Estra) 10-SM and cilostamide (Cilo) 10 M significantly increased
cAMP levels in VSMCs.
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rates in VSMCs. VSMCs were incubated with agents and 50µCi 14C-L-proline for one
hour and were assa1,ed for collagen synthetic levels. Treatment of VSMCs with either
Estradiol (Estra) 10 M or Cilostamide (Cilo) 1-0 5M significantly reduced collagen and
total protein synthetic rates. Treatment of cells with estradiol 1o-5 M + cilostamide 10-6M
had additive effect on both collagen and total protein synthetic rates. Each value represents
the mean .:!:. SE of five to ten observations. * p< 0.05 compared to control cells. ** p< 0.05
compared to estradiol treated cells.

44

12500

-0

**
10000

C

8
0

-

7500

en

i

5000

0..

2500

*

o..L_ _..

1

Estra

Fors

Estra/Fors

Treatment

Fig. 14. The effects of estradiol and forskolin on cAMP levels in VSMCs. VSMCs were
incubated with for one hour and were assayed for cAMP as described in methods. Estradiol
(Estra) 10-SM significantly increased cAMP levels. Forskolin (Fors) 10-sM significantly
increased cAMP levels compared to estrogen treated cells. Estradiol 10-SM
+ forskolin 10-sM appeared to have an additive effect on cAMP levels compared to the cells
treated with just forskolin. Each value represents the mean ±. SE of three
observations. * p< 0.05 compared to control cells. ** p< 0.05 compared to estradiol
treated cells.
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Fig. 15. The effects of estradiol and forskolin on collagen and total protein synthetic
rates in VSMCs. VSMCs were incubated with agents and 2.5µCi 14C-L- proline for one
hour and were assayed for collagen and total protein synthetic levels. Estradiol (Estra) 10·5M
and forskolin (Fors) 10-6 M both significantly reduced collagen and total protein synthesis.
Treatment of VSMCs with estradiol 10·5M+forskolin 10 M
significantly reduced collagen and total protein synthesis compared to estradiol treated
cells Each value represents the mean ±. SE of six observations. * p< 0.05 compared to
control cells ** p< 0.05 compared to estradiol treated cells
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Fig. 16. The effect of estradiol and isoproterenol on cAMP levels in VSMCs. VSMCs
were incubated with agents for one hour and assayed for cAMP. Estradiol (Estra)10-5M,
significantly increased cAMP levels 2 fold, while isoproterenol (lso) 10-e M significantly
increased cAMP levels 5 fold .,The combination of isoproterenol + estrogen appeared to
have an additive effect on cAMP levels. Propranolol (Pro) 10-eM alone had no effect on
cAMP levels, but significantly decreased isoproterenol 's stimulation of cAMP levels
Propranolol had no effect on estrogens ability to increase cAMP levels. Each value
represents the mean .! SE. of at least four observations. * p<0.05 compared to control cells.
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Fig. 17. The effect of estradiol and isoproterenol on collagen synthetic rates in
VSMCs. . VSMCs were incubated with agents and 14C-L-proline for one hour, and were
assayed for collagen synthetic activity as described in methods. Estradiol (Estra) 1o-s M
significantly reduced collagen synthesis by 50%, while isoproterenol (lso) and
propranolol (Pro) had no effect on collagen synthetic activity. .The combination of either
isoproterenol or propranolol with estrogen had no effect on estrogen's ability to inhibit
collagen synthesis. Each value represents the mean ±. SE of five observations. * p<
0.05 compared to control cells.
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Fig. 18. The effect of estradiol and isoproterenol on total protein synthetic rates in
VSMCs. VSMCs were incubated with agents and 14 C-L-proline for one hour, and were
assayed for total protein synthetic activity as described in methods. Estradiol (Estra) 10-5
M significantly reduced total protein synthesis by 50%, while isoproterenol (lso) and
propranolol (Pro) had no effect on total protein synthetic activity. The combination of either
isoproterenol or propranolol with estrogen had no effect on estrogen's ability to inhibit total
protein synthesis. Each value represents the mean + SE of five observations. * p< 0.05
compared to control cells.
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Fig. 19. The effect of a prolonged incubation with isoproterenol on collagen, noncollagen, and total protein synthetic rates in VSMCs VSMCs were incubated with
agent and 14C-L-prolinefor six hours and were assayed for collagen, noncollagen, and
total protein synthetic levels as described in methods. isoproterenol 10-6 M had no effect
on collagen, non-collagen, or total protein synthetic rates. Each value represents the
mean + SE of nine observations. Significance (p< 0.05) compared to control cells.
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Fig. 20. The effect of estradiol and terbutaline on cAMP levels in VSMCs. VSMCs were
incubated with agents for one hour and were assayed as described in methods. Estradiol
(Estra) 10-5 Mand terbutaline (Terb)10-6 M significantly increased cAMP levels 2 -fold.
Treatment of VSMCs with estradiol 10·5 M + terbutaline 10-6 M had an additive, elevating
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* p< 0.05 compared to control cells. ** p< 0.05 compared with estradiol treated cells.
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Fig. 21. The effect of estradiol and terbutaline on collagen and total synthetic
rates in VSMCs. VSMCs were incubated with agents and 2.5µCi of 14C-L-proline for
one hour and were assayed for collagen and total synthetic levels as described in
methods. Estradiol (Estra) 10-5 M significantly reduced collagen and total synthesis.
Treatment of VSMCs with estradiol 10-SM + terbutaline 1o-oM also significantly reduced
both collagen and total protein synthesis. Terbutaline 10-0 Malone had no effect on
collagen or total protein synthesis. Each value represents the mean ± SE of three
observations. * p<0.05 compared to control cells
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Fig. 22. The effects of estradiol and terbutaline on intracellular and extracellular cAMP
levels in VSMCs. VSMCs were incubated with agents for one hour, and the medium and
cellular extracts were assayed for cAMP as described in methods.
Treatment of VSMCs with Terbutaline (Terb) 10-6M resulted in 90% of total cAMP in the
extracellular environment. Control and estradiol (Estra) 10.sM treated cells had significantly
less cAMP in the extracellular milieu and significantly more cAMP intracellularly
compared to the terbutaline treated cells. Each value represents the mean.
± SE of eight observations. * p< 0.05 compared to control cells.
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Discussion

The use of estrogens in postmenopausal women has recently become
controversial. Estrogen replacement therapy has been used for many years to
slow the progression of atherosclerosis. Recent studies have suggested that
estrogen replacement therapy may inflict harmful effects, such as myocardial
infarcts and strokes than beneficial effects. Estrogens have been shown to
inhibit collagen synthesis (Dubey et al. 1998). Collagen is known to have an
important role

in atherosclerotic lesions, and its accumulation within

atherosclerotic lesions is known to promote narrowing of the arterial lumen and
may serve as a depot for macromolecules (i.e., lipoproteins and growth factors).
Other studies have suggested that collagen may add to lesion stability (Rekhter
et al., 1999) and that a decrease in collagen can make atherosclerotic lesions
vulnerable to rupture, which may promote the formation of vessel-occluding
blood clots. These data suggest that either too much or too little collagen within
atherosclerotic lesions could have a negative effect on blood flow in diseased
blood vessels. The mechanism by which estrogen treatment reduces collagen
synthesis is not completely understood but is probably related to estrogens ability
to increase cell levels of cAMP. The hypothesis, which was investigated in this
study, was the following: agents, which elevate cAMP in VSMC, when used in
combination with estrogen, will have an additive effect in inhibiting collagen
synthesis in VSMC.
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There are many studies that show estrogen eliciting a fast-acting
biological response through nongenomic processes in a variety of cell types
(Dos Santos et al., 2002, Cambiasso et al., 2001, and Farhat et al., 1996). Our
results demonstrate that increasing concentrations of estrogen (10-6M, 10-5M, 104M) resulted in elevated levels of cAMP in VSMCs and that estrogen at a dose of
10-5M can increase cAMP levels 2-fold within 1 hour.(Fig. 6). These results agree
with recent study data by Farhat et al., (1996) and Dubey et al., (2000), which
demonstrated that estrogen may induce cAMP within 5-30 minutes in VSMCs.
Farhat et al. further demonstrated that estrogen increases cAMP levels by
stimulating adenylate cyclase activity through a calcium-dependent process.
Estrogen is an inhibitor of collagen synthesis in VSMCs; however, the exact
mechanism is not known. One of the first studies investigating estrogen effects
on collagen synthesis showed that estrogen inhibited total collagen production
and reduced procollagen type 1 and type 2 fractions in bovine aortic smooth
muscle cells (Beldekas et al., 1981 and Dubey et al.2000), demonstrated that
estrogen, increased cAMP levels, which resulted in inhibition of both, total
protein and collagen synthesis. The results from our studies agree with the
findings of Dubey et al., In our study, VSMCs treated with increasing
concentrations of estrogen displayed decreasing rates in both collagen and
noncollagen protein synthesis in addition to increasing levels of cAMP,
suggesting a dose response relationship (Fig.7). When collagen synthetic rates
in VSMCs were compared to cellular levels of cAMP, there was an apparent
inverse correlation, indicating that as cellular levels of cAMP increased,
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a related reduction in collagen synthesis followed. (Fig. 8). The mechanism by
which increased cAMP levels reduces rates of collagen synthesis is unknown.
Dubey and colleagues suggested that estrogen inhibits protein synthesis in
VSMCs by activating a cAMP-adenosine pathway (Dubey et al., 2000). In this
pathway, extracellular adenosine levels are elevated by the transport of cAMP to
the extracellular space where the cAMP is converted to AMP by ectophosphodiesterase (ECTO-PDE) and subsequently to adenosine (ADO) by ecto5'-nucleotidase(ECT0-5'-NT) (Fig 23).

Smooth Muscle Cell
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ATP

Inhibition
Fig. 23 A schematic showing the cAMP-adenosine pathway in VSMCs
Dubey et al., 2000. Hypertension 35:262-6

The newly formed adenosine binds the adenosine, subtype 2 receptor,
(A2) , which has an inhibitory effect on collagen and total protein synthesis.
These data suggested to Dubey et al. that the inhibitory effects of estrogen are
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mediated through the cAMP-adenosine pathway and not by activation of intracellular
protein kinase A (PKA) activity.
The results of these studies, using the phosphodiesterase inhibitor,
pentoxifylline, showed that by preventing breakdown of cAMP, the cAMP-protein
kinase A (PKA) pathway may be activated, and this resulted in inhibition of collagen
synthesis in VSMCs (Chen et al., 1999). Co-incubation of pentoxifylline with H-89, a
selective inhibitor of PKA, prevented the pentoxifylline induced inhibition of collagen
synthesis. Since estrogen treatment increases cAMP levels, the role of the cAMPPKA pathway in suppressing collagen and total protein synthesis in estrogen- treated
VSMC tissue culture model was explored. Co-treatment of VSMCs with estrogen
and Rp-cAMP, a PKA inhibitor, significantly reduced estrogen's ability to inhibit
collagen and total protein synthesis in VSMCs (Fig.9). These data suggest that in
our model, estrogen attenuates protein synthesis by activating the cAMP-PKA
effector pathway. In support of our data, other studies by Walsh et al., (1994), have
found that PKA can halt translation of proteins by phosphorylating the initiation factor
elF-2. Possibly, estrogen may impair collagen synthesis by activating a cascade of
kinases, which are switched on by the PKA pathway.
To determine if the inhibition of cAMP breakdown to AMP by PDE can
block the collagen/protein reduction effects of estrogen as suggested by the
studies of Dubey et al., VSMCs were treated with two different PDE inhibitors.
Treatment of VSMCs with cilostamide, a phosphodiesterase type Ill inhibitor or
Ro-20-1724, a phosphodiesterase type IV inhibitor, resulted in

57

increased cAMP levels (Fig. 10 and 12) and decreased rates of collagen and
total protein synthesis (Fig. 11 and 13). Since cilostamide appears to be less
potent than Ro-20-1724 in elevating cell cAMP levels, it is tempting to speculate
that inhibition of PDE type IV is more effective than PDE type Ill in elevating
cAMP levels. Additional dose response studies using both agents would be
necessary to confirm this.
Treatment of VSMCs with estrogen and cilostazol or Ro-20-1724 had an additive
effect on cAMP levels (Fig. 10 and 12) and on inhibition of collagen and total
protein synthetic rates ( Fig. 11 and 13). Contrary to the studies by Dubey et al.,
these findings suggest that the breakdown of cAMP to AMP and subsequently to
adenosine may not be a necessary process for inhibiting protein synthesis in
VSMCs. The results of our studies using a PKA inhibitor and phosphodiesterase
inhibitors are consistent with the hypothesis that estrogen- induced changes in
cAMP activates the cAMP-PKA effector pathway to attenuate protein synthesis
in VSMCs.
The phosphodiesterase inhibitor data (cilostamide and Ro-20-1724) appear
not to support Dubey's hypothesis that estrogen utilizes the cAMP- adenosine
pathway to inhibit collagen synthesis. Instead, our data suggest that estrogeninduced cAMP is not required to be converted to adenosine to inhibit collagen
synthesis. The co-incubation of cilostamide or Ro-20-1724 phosphodiesterase
inhibitor with estrogen produced an additive effect on cAMP levels and collagen
inhibition.

Furthermore,

our

beta-adrenergic

agonist

data

bolsters

our

phosphodiesterase inhibitor data because it demonstrates that the beta-adrenergic
receptor is not involved with collagen inhibition since
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more of its cAMP is exported to the extracellular compartment.
As shown in figures 11 and 13, the level of protein synthesis inhibition is
approximately the same in VSMCs treated with cilostamide or Ro-20-1724 even
though Ro-20-1724 caused a greater increase in cAMP compared to cilostamide
treated cells. A possible explanation for this observation is that not all the cAMP
generated by blocking the PDE was available to inhibit protein synthesis. Studies
have shown that cAMP can be compartmentalized within the cell and used for
activating separate pathways to elicit distinct biological responses. For example,
compartmentation studies in the perfused heart have compared effects of forskolin
and isoproterenol on cAMP accumulation and cardiac tension. England et al., (1987)
found that, at approximately equal cardiac tensions, the levels of cAMP elicited by
isoproterenol were generally smaller than those levels elicited by forskolin. When
increased concentrations of isoproterenol were used to elevate cAMP to similar
levels of forskolin treatment, the cardiac tensions were larger with isoproterenol than
those observed with forskolin. England et al. concluded that only a portion of the
total cAMP, induced by forskolin, may be responsible for the measured cardiac
effects and that the remaining cAMP may be collected within intracellular
compartments involved in different cellular functions. Similar observations were
made in studies of the relationship of cAMP and the modulation of Ca2 + movement
through cell membrane calcium channels of isolated canine ventricular myocytes
(Hohl et al.,1991).
+
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Ca2+ correlated best with amount of cAMP in the particulate fraction. As a result,
treatment of myocytes with isoproterenol resulted in a greater proportion of total
cAMP in the particulate fraction than with forskolin treatment. Since isoproterenol
had a greater effect on calcium movement than forskolin, Hohl & Li hypothesized
that, in myocytes, differences in responses to agents that increased cAMP may be
explained in part by compartmentalization of cAMP.
In our experiments, forskolin treatment of VSMCs elevated cAMP levels
(Fig 14) and suppressed collagen and total protein synthesis (Fig. 15). This
finding agrees with Dubey et al. (2000) who reported that forskolin treatment has
an inhibitory effect on collagen synthesis in VSMCs. Our studies showed that coincubation of VSMCs with estrogen and forskolin produced an additive effect on
cAMP production (Fig. 15) and an inhibitory effect on collagen and total protein
synthesis (Fig. 16). Although the levels of cAMP induced by forskolin (Fig. 15)
exceeded those induced by estrogen, collagen and total protein inhibition (Fig.
16) for all these agents was similar (~50% of controls). Based upon the studies
by England et al., (1987) and Hohl (1991), it can be hypothesized that the bulk
of the cAMP induced by forskolin may be compartmentalized for alternative
functions not related to protein synthesis. Studies in human fetal lung fibroblasts
have shown that treatment of cells with isoproterenol, a beta adrenergic, agonist,
significantly elevated cAMP content and inhibited collagen synthesis (Baum et
al., 1981). In our studies, treatment of VSMCs with isoproterenol significantly
increased cAMP levels in VSMCs (Fig.
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16). As expected, the addition of propranolol, a beta- adrenergic antagonist, to
isoproterenol treated cells significantly reduced the level of cAMP, which was
observed in cells treated with isoproterenol alone. Propranolol had no effect on
estrogen's ability to inhibit cAMP which was not surprising since estrogen has
been reported to increase cAMP levels by directly stimulating adenylyl cyclase
activity.(Farhat et al., 1996).
Surprisingly, isoproterenol had no inhibitory effects on collagen or total
protein synthetic rates even though isoproterenol treatment of VSMCs significantly
elevated cell cAMP levels (Fig. 16, 17 and 18). Studies by Crystal et al. (1981)
reported that a 6- hour incubation of lung fibroblasts with isoproterenol resulted in a
decrease in collagen synthetic rates. Since our VSMCs were incubated with
isoproterenol for only 1 hour, a 6-hour incubation study was conducted. As seen in
figure 19 a 6- hour incubation did not result in any significant alteration in collagen
or total protein synthetic rates, suggesting that there may be a fundamental
physiological difference

between

lung

fibroblasts and VSMCs. Treatment of

VSMCs with isoproterenol and estrogen had an additive effect on cAMP levels
(Fig.16) but had no additive effect on collagen and total protein synthesis (Fig 17 and
18). The level of inhibition of cellular protein synthesis by this type of combination
treatment was similar to the level of inhibition with estrogen treatment alone (Fig.
17 and 18).
VSMCs primarily have beta2 adrenergic receptors that regulate
vasodilation under normal physiological conditions (Vatner et al., 1986). Since
isoproterenol is a nonspecific beta agonist, terbutaline , a selective beta2-
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adrenergic receptor agonist, was utilized in our studies to further characterize the
relationship of beta stimulated increases in cAMP and protein synthetic rates.
Treatment of VSMCs with terbutaline resulted in a significant increase in cAMP
levels, which was similar to estrogen's effects but was much less than the cAMP
changes induced by isoproterenol (Fig. 20). As seen with isoproterenol,
terbutaline also had no effect on protein synthesis in VSMC when administered
to VSMCs either alone or in combination with estrogen (Fig. 21).
Numerous studies have shown that activation of the beta-adrenergic
receptor can mediate transport of cAMP to the extracellular compartment, where
it can serve an essential cellular function (Rosenberg et al., 1995). For example,
in cortical cultures, which are co-cultures of neurons and astrocytes, upon
isoproterenol stimulation of the beta-adrenergic receptor, cAMP is exported out
from astrocytes to the extracellular compartment where it is hydrolyzed to
adenosine (Rosenberg et al., 1995). These data suggest that the extracellular
transport of cAMP is essential in replenishing adenosine levels, which are
necessary for neuromodulation in the cerebral cortex (Rosenberg et al. 1995). In
our studies, estrogen and the beta agonists, isoproterenol and terbutaline, had
induced cAMP, but only estrogen inhibited protein synthesis in VSMCs,
indicating that estrogen and beta agonist stimulation of cAMP levels result in
some form of compartmentalization of cAMP within VSMCs. To further examine
this hypothesis VSMCs were treated with either estrogen or terbutaline, and the
distribution patterns of cAMP

were measured. In VSMCs, treated with

terbutaline, the distribution pattern of cAMP was 90%
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extracellular and 10% intracellular, while in VSMCs, treated with estrogen, the
cAMP distribution pattern was 70% extracellular and 30% intracellular. The
distribution of cAMP following estrogen treatment was similar to the distribution
of cAMP seen in untreated VSMCs. (Fig. 22). These data suggest that the
transport of cAMP to the extracellular compartment following treatment with a
beta agonist may explain why beta -adrenergic stimulation of cAMP in VSMCs
does not result in inhibition of protein synthesis in VSMCs. (Fig.22). Since betaadrenergic stimulation results in increased levels of cAMP in the extracellular
compartment, it further questions the significance of the adenosine pathway as
described by Dubey et al. (2000) in regulating protein synthesis in VSMCs.
Conclusion
The hypothesis, which was investigated in this study, was that agents which
elevate cAMP in VSMC when used in combination with estrogen will have an
additive effect in inhibiting collagen synthesis in VSMC. Our studies found that
phosphodiesterase Ill inhibitor, cilostamide, phosphodiesterase IV inhibitor, Ro-241724. and forskolin in combination with estrogen had additive effects on estrogen
induced cAMP levels and on estrogen reduced collagen synthetic rates, while betaadrenergic agonists, isoproterenol or terbutaline, when used in combination with
estrogen were able to elicit an additive effect on cAMP levels but had no effect on
collagen synthetic rates.

Furthermore,

our studies show that once the beta-

adrenergic receptor stimulation induces cAMP, it is actively transported to the
extracellular milieu. These data suggest that the loss of most cAMP due to its
transport out of the cell may be the reason why
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beta- adrenergic receptor stimulation is unable to inhibit collagen synthesis in
VSMCs.
Our study has shown that estrogen and other camp elevating agents, such
as cilostamide, Ro-20-1724, and forskolin, have an inhibitory effect on collagen
synthesis in VSMCs. It is well established that during the later stages of lesion
development reducing collagen content in lesions may weaken lesions and
cause them to rupture. The clinical significance of the data is that estrogen
replacement therapy and medications which elevate cAMP may reduce collagen
levels in lesions, causing them to eventually rupture. Furthermore, our data also
suggest that the combination of these agents, which have an additive effect on
estrogen, may have a negative effect on the stability of existing atherosclerotic
lesions by inhibiting collagen synthesis.
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